QIAGEN’s VP and Head of PCR Business, Michael Scheffler, discusses the QIAcuity system and how it helps biopharma customers with drug discovery and development. He also talks about QIAGEN customizing assays for customers and providing access to specialized multiplex assays. Scheffler emphasizes the advantages of digital PCR for improving drug safety and efficacy.
Michael Scheffler holds an MSc in Engineering from the Technical University Berlin, and a PhD from ETH Zurich, respectively. After graduating he joined a Swiss SME startup for five years, providing contract development services around medical device miniaturization, serving in the executive management as well as a board member. Now with QIAGEN for more than 15 years, Scheffler has held several R&D and program management positions. During this time he introduced several purification and detection platforms (QIAcube, RotorGene, QIAcuity) as well as regulated diagnostic applications into the market. Recently he took over responsibility for the Life Science PCR business.